Esperion Therapeutics Inc. [NASDAQ: ESPR] traded at a low on Friday, posting a -3.90 loss after which it closed the day’ session at $2.22.
The results of the trading session contributed to over 61367982 shares changing hands. Over the past one week, the price volatility of Esperion Therapeutics Inc. stands at 11.71% while the volatility over the past one month is 9.65%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ESPR stock reached $378.33 million, with 170.42 million shares outstanding and 154.70 million shares in the current float. Compared to the average trading volume of 7.85M shares, ESPR reached a trading volume of 61367982 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Esperion Therapeutics Inc. [ESPR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $7.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.88. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 20, 2024. The new note on the price target was released on January 03, 2024, representing the official price target for Esperion Therapeutics Inc. stock.
The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.24, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 1.65.
How has ESPR stock performed recently?
Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.45. With this latest performance, ESPR shares gained by 2.30% in over the last four-week period, additionally sinking by -21.55% over the last 6 months – not to mention a rise of 60.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 43.66, with the RSI for the last a single of trading hit 40.03, and the three-weeks RSI is set at 45.95 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.29, while it was recorded at 2.20 for the last single week of trading, and 1.96 for the last 200 days.
Esperion Therapeutics Inc. [ESPR]: Deeper insight into the fundamentals
Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.78 and a Current Ratio set at 2.22.
Earnings analysis for Esperion Therapeutics Inc. [ESPR]
With the latest financial reports released by the company, Esperion Therapeutics Inc. posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.61/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 24.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.
Insider trade positions for Esperion Therapeutics Inc. [ESPR]
The top three institutional holders of ESPR stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in ESPR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in ESPR stock with ownership which is approximately 5.8386%.
